Global Real World Data Tour: 2024 Key Insights
Webinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Join our webinar to discover the Real World Data needed to generate evidence and answer critical research questions. Gain insights into healthcare systems and unique datasets from North America, Europe, Asia Pacific, and Latin America to understand healthcare trends, treatment approaches, and market dynamics.
Register Free: https://www.pharmexec.com/pe_w/real-world-data-tour
Event Overview:
Calling all Real World Data researchers! Missed the Global Health Data Passport Webinar Series?
Join this webinar to take a data landscape world tour of the 2024 series highlights. Explore unique datasets from each region, covering key therapeutic areas, to gain faster insights into healthcare trends, treatment approaches, and market dynamics. Discover the Real World Data sources you need to generate evidence and answer critical research questions.
Three key take-aways
- Gain insights into healthcare systems and available data assets from countries throughout North America, Europe, Asia Pacific, and Latin America.
- Learn how to streamline multi-country studies by leveraging a common data model for rapid comparative analyses across diverse countries and datasets
- Discover how to rapidly identify data and accelerate your analysis with AI, machine learning, and data linking to visualize the full patient journey
Speakers
Megan Califano
Director, Offering Management
IQVIA USA
Alan Thomas
Senior Director, Strategic Planning
IQVIA Japan
Paul Berg
Senior Principal, Real World Solutions
IQVIA UK
Ramon Pereira
Head of Data Science
IQVIA Brazil & LATAM
Ken Chin
Senior Consultant
IQVIA Australia
Long Pang
Engagement Manager
Real World Solutions, IQVIA
China
Andrzej Mazurek
Engagement Manager
IQVIA Poland
Sarah Seager
Senior Director, Analytics & AI
IQVIA Global
Register Free: https://www.pharmexec.com/pe_w/real-world-data-tour
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
